[Translation] Single-arm, multicenter, phase Ib/II study of IBI310 (anti-CTLA-4) combined with sintilimab in advanced biliary tract cancer progressing after standard therapy
评价IBI310联合信迪利单抗在既往接受过至少1线标准治疗后进展的晚期胆道癌患者中的疗效
[Translation] To evaluate the efficacy of IBI310 combined with sintilimab in patients with advanced biliary tract cancer who have progressed after at least 1 line of standard therapy